CME

Podcast

Cases & Conversations: Integrating Novel Approaches to Treatment in First-Line ALK+ mNSCLC Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this Oncology PER® Spectives™ podcast episode, join 3 leading experts in oncology as they explore innovative approaches to treating ALK+ metastatic non-small cell lung cancer (mNSCLC). This engaging discussion focuses on molecular testing as the foundation of personalized therapy, the latest evidence on first-line therapies, and the vital role of multidisciplinary care for enhancing patient outcomes. Topics include selecting from available targeted therapies, overcoming barriers to comprehensive molecular diagnostics, and managing treatment-related adverse events. Tune in to gain actionable insights that will empower healthcare professionals to deliver optimized, guideline-driven care to patients with ALK+ mNSCLC.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Takeda Pharmaceuticals USA, Inc.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Instructions on How to Receive Credit

  • Listen to this podcast in its entirety.
  • Go to gotoper.com/credit and enter code: 6174
  • Answer the evaluation questions.
  • Request credit using the drop-down menu.
  • You may immediately download your certificate.

Today’s faculty are:

Mark G. Kris, MD

William and Joy Ruane Chair in Thoracic Oncology
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Merck.

Justin Gainor, MD

Associate Professor of Medicine
Harvard Medical School
Program Director, Center for Thoracic Cancers
Director, Targeted Immunotherapy
Massachusetts General Hospital
Boston, MA

Disclosures: Grant/Research Support Paid to Institution: Adaptimmune, Alexo, Array BioPharma, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Jounce Therapeutics, Merck, Moderna, Novartis, Palleon Pharmaceuticals, Tesaro; Consultant: Bristol Myers Squibb, Genentech/Roche Group, Gilead Sciences, iTeos Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Loxo Oncology/Lilly, Mariana Oncology, Merck, Merus, Mirati Therapeutics, Moderna, Novartis, Novocure, Nuvalent, Pfizer, Silverback Therapeutics, Takeda.

Isabel Preeshagul, DO, MBS

Thoracic Medical Oncologist
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
Montvale, NJ

Disclosures: Scientific Advisory: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, GI Therapeutics, Pfizer, Regeneron, Takeda.

Helena A. Yu, MD

Thoracic Medical Oncologist and Early Drug Development Specialist
Associate Attending Physician
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Consultant: AbbVie, Amgen, AstraZeneca, Bristol Myers Squibb, Cullinan, Daiichi Sankyo, Ipsen, Janssen, Takeda; Other: Data and Safety Monitoring Board: Janssen, Mythic Therapeutics.

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Release Date

January 21, 2025

Expiration Date

January 21, 2026